ロード中...

Regression of brain metastases from breast cancer with eribulin: a case report

BACKGROUND: Eribulin is a recently approved new therapeutic option for patients with metastatic breast cancer. According to several reports, eribulin has limited ability to cross the blood brain barrier. Recently, capecitabine and eribulin have been recognized as drugs with similar application for p...

詳細記述

保存先:
書誌詳細
主要な著者: Matsuoka, Hiromichi, Tsurutani, Junji, Tanizaki, Junko, Iwasa, Tsutomu, Komoike, Yoshifumi, Koyama, Atsuko, Nakagawa, Kazuhiko
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2013
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3878316/
https://ncbi.nlm.nih.gov/pubmed/24350786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-0500-6-541
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!